Setmelanotide Beneficial in Acquired Hypothalamic Obesity

WEDNESDAY, July 22, 2026-- For patients aged 4 to 66 years with acquired hypothalamic obesity, setmelanotide leads to significantly greater reductions in body mass index (BMI) and hunger than placebo, according to a study published in the July 9...